European Heart Journal Advance Access originally published online on December 21, 2007
European Heart Journal 2008 29(2):166-176; doi:10.1093/eurheartj/ehm518
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
1 Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
2 Nordic School of Public Health, Göteborg, Sweden
Received 24 June 2007; revised 11 October 2007; accepted 18 October 2007; online publish-ahead-of-print 21 December 2007.
* Corresponding author. Tel: +46 8 51772171, Fax: +46 8 344964, Email: linda.mellbin{at}karolinska.se
See page 141 for the editorial comment on this article (doi:10.1093/eurheartj/ehm595)
Aims: To explore the impact of glucose lowering treatment on prognosis in diabetic patients with myocardial infarction.
Methods and results: 1181 type 2 diabetic patients (mean age 68 years; 67% males) discharged after myocardial infarction were followed (median of 2.1 years). At discharge, 436 patients (37%) had oral glucose lowering agents whereof 268 sulphonylureas and 200 metformin, while 690 patients (58%) were on insulin. The impact of treatment was analysed by an updated Cox proportional hazards regression model, correcting for confounders. Cardiovascular mortality was not influenced by metformin [Hazard ratio (HR) 0.93, 95% CI 0.60–1.43; P = 0.73], sulphonylureas (HR 1.15, 95% CI 0.80–1.64; P = 0.45), or insulin (HR 1.05, 95% CI 0.75–1.46; P = 0.77). The risk for non-fatal myocardial infarction and stroke increased significantly in patients on insulin (HR 1.73, 95% CI 1.26–2.37; P = 0.0007), whereas this risk was lower among those on metformin (HR 0.63, CI 0.42–0.95; P = 0.03) and unchanged with sulphonylureas (HR 0.81, 95% CI 0.57–1.14; P = 0.23). This finding remained analysing only patients with newly instituted insulin and those randomly allocated to newly instituted insulin.
Conclusion: Controlling for confounders including glycemic control, there was no significant difference in mortality between sulphonylureas, metformin, and insulin. In this post hoc analysis, the risk of non-fatal myocardial infarction and stroke increased significantly by insulin treatment while metformin was protective. It is emphasized that this observation is done in an epidemiological analysis and should encourage to further confirmation in randomized trials.
Key Words: Myocardial infarction • Diabetes mellitus • Sulphonylurea • Metformin • Insulin • Cardiovascular events
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Glucose-lowering therapy after myocardial infarction: more questions than answers
- Peter W. Radke and Heribert Schunkert
EHJ 2008 29: 141-143.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  B. Hemmingsen, S. S Lund, J. Wetterslev, and A. Vaag Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes Eur. J. Endocrinol., July 1, 2009; 161(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L G Mellbin, K Malmberg, A Waldenstrom, H Wedel, L Ryden, and for the DIGAMI 2 investigators Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial Heart, May 1, 2009; 95(9): 721 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Garcia and P. Lopez-Jaramillo Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it? Eur. Heart J., August 2, 2008; 29(16): 2058 - 2058. [Full Text] [PDF]
|
|
|
|
|
|
L. G. Mellbin, L. Ryden, K. Malmberg, A. Norhammar, and H. Wedel Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it?: reply Eur. Heart J., August 2, 2008; 29(16): 2058 - 2059. [Full Text] [PDF]
|
|
|
|
|
|
U. N. Das Glucose, insulin, and coronary heart disease Eur. Heart J., April 2, 2008; 29(8): 1075 - 1076. [Full Text] [PDF]
|
|
|
|
|
|
P. W. Radke and H. Schunkert Glucose-lowering therapy after myocardial infarction: more questions than answers Eur. Heart J., January 2, 2008; 29(2): 141 - 143. [Full Text] [PDF]
|
|
|
|
|
|
M. Anselmino, J. Ohrvik, K. Malmberg, E. Standl, L. Ryden, and on behalf of the Euro Heart Survey Investigators Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart Eur. Heart J., January 2, 2008; 29(2): 177 - 184. [Abstract] [Full Text] [PDF]
|
|